FibroBiologics (FBLG) Total Current Liabilities (2022 - 2026)

FibroBiologics (FBLG) has reported Total Current Liabilities for 5 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 79.82% year-over-year to $2.2 million; the trailing twelve-month figure through Jun 2026 stood at $2.2 million (down 79.82% YoY), and the FY2025 full-year result was $1.8 million, down 86.18% from the prior year.
• Total Current Liabilities grew to $2.2 million in Q2 2026 per FBLG's latest filing, from $1.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $14.0 million in Q1 2024 and bottomed at $1.8 million in Q4 2025.
• Historically, Total Current Liabilities has averaged $7.6 million across 5 years, with a median of $7.6 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities jumped 38.58% in 2024, then tumbled 86.18% in 2025.
• Over 5 years, Total Current Liabilities stood at $7.1 million in 2022, then grew by 29.83% to $9.2 million in 2023, then surged by 38.58% to $12.7 million in 2024, then sank by 86.18% to $1.8 million in 2025, then advanced by 25.81% to $2.2 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $2.2 million, $1.8 million, and $1.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.